LIB820 / Liberate Bio - LARVOL DELTA

Latest preclinical data support promise of CAR-M cell therapy LIB820 (Multiple Sclerosis News Today) - "The findings, presented last week at the American Society of Gene and Cell Therapies annual meeting in Boston, support plans to launch an investigator-initiated clinical trial in diffuse cutaneous systemic sclerosis, an autoimmune disease also driven by B-cell activity, that’s expected to begin by the end of the year...But according to the company, the initial clinical focus will also include MS and lupus, another autoimmune disease....Newer in vivo CAR T-cell therapies, which genetically modify T-cells directly inside the patient’s body, have been explored to overcome these challenges. However, CAR T-cell therapies remain associated with concerns about serious side effects, including cytokine release syndrome (CRS), a potentially life-threatening inflammatory reaction, and neurotoxicity linked to excessive T-cell activation."

New trial • Preclinical • Immunology • Lupus • Multiple Sclerosis • Systemic Sclerosis

Liberate Bio, Inc…announces that it has secured exclusive and non-exclusive licenses to key patents covering chimeric antigen receptor (CAR) designs optimized for myeloid cells, including monocytes and macrophages. (Businesswire) - "With both optimized CAR-sequence IP and cell-selective delivery technology, Liberate Bio now integrates the critical components needed to advance in vivo CAR-M therapies toward clinical evaluation....Liberate Bio plans to advance its first in vivo CAR-M candidate toward IND-enabling studies, with the goal of supporting the first clinical evaluation in the second half of 2026 through an investigator-initiated trial."

Licensing / partnership • New trial • Oncology